CONFERENCE DAY two

SEPTEMBER 10, 2025

SHOWCASE YOUR SCIENCE CONTINUED

7:30 – 8:30 One-on-One PartneringTM portal meeting schedule starts. Arrive early to grab a coffee and meet with key contacts in bookable meeting spaces before the conference begins.

7:30 am Chair’s Opening Remarks

  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics

Target Selection & Novel Conjugates

Synopsis

Opportunities to be First-in-Class & Differentiate through Design, to More Selectively Target or Effectively Internalize Payloads into Target Cells

8:40 am Session Reserved for GO Therapeutics

9:00 am Session Reserved for MaveriX

  • Steven Everett Founder, President & Chief Executive Officer, MaveriX Oncology Inc.

9:30 – 11:30 One-on-One Meeting Schedule Available During Extended Break

Synopsis

With Day One an opportunity to establish connections and break the ice, leverage extended breaks during Day Two’s schedule to sit down with slide decks and make a lasting impression. Beyond the breaks, gain insiders insights into how business leaders across payloads, novel conjugates, linker conjugation, and target selection technologies are creatively shaping deal-making and prioritizing science that’s poised to lead in the race for first- or best-in-class. 

9:40 am Morning Break & Networking

11:40 am Opportunity to be First-in-Class: Considerations for Collaborations with New Targets

  • Robin Carr Chief Executive Officer, Myricx Bio
  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics
  • Matthew Metzger Program, Alliance & Business Development Manager, Oxford BioTherapeutics
  • Ajla Hrle Chief Business Officer, DISCO Pharmaceuticals GmbH
  • Kinney Horn Chief Business Officer, Immunome Inc.
  • Valerie Vanhooren Co-Founder & Chief Executive Officer, ONA Therapeutics

Synopsis

  • What are the economics of having a new target for others to develop an ADC around?
  • Discussing opportunities to be first-in-class pursuing underexploited targets 
  • Debating the decision to leverage the best linker-payload platform or off-patent technologies, considering the influence on the side effect profile

12:15 pm Lunch Break & Networking

12:30 – 2:00 One-on-One Meeting Available During Extended Lunch

2:10 pm Increasing Tissue Penetration & Limiting Immunogenicity: Differentiating Through Novel Conjugate Design

  • Arne Scheu Co-Founder & Chief Executive Officer, Valink Therapeutics
  • Joe Nabhan Chief Scientific Officer, K2B Therapeutics Inc.
  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics
  • Caitlyn Miller Co-Founder & Chief Executive Officer, TwoStep Therapeutics

Synopsis

  • Targeting proteins expressed in a larger number of cancers versus receptors predominantly expressed in solid tumor subsets
  • Increasing tissue penetration propensity to achieve more significant internalization and intracellular exposure to the payload with smaller proteins 
  • Leveraging reduced screening cycles required to optimize linker chemistry with smaller proteins, and modulatory to conjugate different payload types

ADC Deal-Making: Experience & Economics of Successful Partnerships in ADCs

2:45 pm ADC Deal-Making: Will Success Lead to More Success?

  • John Mayfield Senior Vice President - Business Development & Strategy, Flagship Pioneering
  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics
  • Filippo Mulinacci Chief Business Officer, Araris Biotech AG
  • Tim Wang Chief Business Officer, Duality Biologics
  • Matthew Metzger Program, Alliance & Business Development Manager, Oxford BioTherapeutics
  • Barbara Leyman Chief Business Officer, Sutro Biopharma

Synopsis

  • Discussing opportunity for and examples of creative deal structures across ADCs 
  • For payloads: Do you need the full ADC payload for a deal?
  • For linkers: What drives deals with different types of linkers? 
  • For target discovery: What are the differences in deal structure versus linkers and payloads?
  • Sharing guidance to progress from a research collaboration to a licensing agreement, and deal structure including direction for upfront milestones and royalties

3:20 pm Chair’s Closing Remarks

  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics

3:30 pm Conference “In Session” Agenda Finished

Coffee Refreshed & Meeting Space Kept Available for Meeting Opportunities